# Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

> **NCT01989845** · PHASE4 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 127 (actual)

## Conditions studied

- Rivaroxaban
- Cancer-associated Thrombosis
- Recurrence
- Bleeding

## Interventions

- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT01989845
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2017-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989845, "Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01989845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*